The moral imperative: Balancing innovation, regulation and

The moral imperative: Balancing innovation, regulation and prescription drug availability

Listen now

Description

In this episode, DLA Piper's Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky, founding Partner and Portfolio Manager at RA Capital, to discuss the importance of – and complications in – balancing biopharmaceutical innovation, industry regulations and prescription drug availability. See omnystudio.com/listener for privacy information.

More Episodes

See all »

Life sciences companies and the risks posed by the mifepristone litigation

In this episode, a cross-disciplinary team of FDA regulatory lawyers and life sciences litigators discuss the implications of the mifepristone litigation for life sciences companies as it pertains to citizen petitions, FDA approvals, and strategies manufacturers might consider going forward. See...

Published 05/19/23

At the Intersection of Science and Law

Published 05/19/23

Trade secrets protection in the life sciences sector

DLA Piper’s Roberto Valenti and Ray Miller discuss trade secrets protection in the US and Europe and the peculiarities within the life sciences sector. Our speakers provide pragmatic approaches and suggestions on how to manage trade secrets for both pharmaceutical companies and medical device...

Published 04/12/23